Comparison of the Effectiveness of Greater Occipital Nerve and Supratrochlear Nerve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chronic Migraine
- NCT ID
- NCT07837570
- Registry status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- Assiut University
- Conditions
- Chronic Migraine
Overview
ClinicalTrials.gov lists this study as Not yet recruiting.
Enrollment: 70 participants (Estimated).
What is being studied
- Intervention: Amino Acids, Peptides, and Proteins
- Intervention: Bacterial Proteins
- Intervention: Bacterial Toxins
- Intervention: Biological Factors
- Intervention: Botulinum Toxins
- Intervention: Botulinum Toxins, Type A
- Intervention: Endopeptidases
- Intervention: Enzymes
- Intervention: Enzymes and Coenzymes
- Intervention: Hormones
- Intervention: Hormones, Hormone Substitutes, and Hormone Antagonists
- Intervention: Hydrolases
- Intervention: Hypothalamic Hormones
- Intervention: Metalloendopeptidases
- Intervention: Metalloproteases
- Intervention: Nerve Tissue Proteins
- Intervention: Neuropeptides
- Drug: OnabotulinumtoxinA
- Intervention: Peptide Hormones
- Intervention: Peptide Hydrolases
- Intervention: Peptides
- Intervention: Prolactin-Releasing Hormone
- Intervention: Proteins
- Intervention: Toxins, Biological
- Procedure: Ultrasound-guided pulsed radiofrequency (PRF) of the greater occipital nerve (GON) and supratrochlear nerve
Who may be eligible
- Ages
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers accepted
- No
ClinicalTrials.gov lists the following eligibility criteria.
Inclusion Criteria:
* Age between 18 and 65 years, either sex.
* Diagnosis of chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria (headache occurring on ≥15 days/month for \>3 months, with migrainous features on ≥8 days/month).
* Inadequate response, intolerance, or contraindication to at least one standard oral preventive medication (e.g., amitriptyline, propranolol, topiramate, flunarizine, valproate).
* Stable dose of any concurrent prophylactic medication for at least 4 weeks prior to enrolment, with no planned change during the study period.
* Willingness and ability to complete headache diaries and follow-up visits.
Exclusion Criteria:
* • Other primary headache disorders (tension-type headache, cluster headache, hemicrania continua) as the predominant headache type.
* Secondary headache due to an identifiable structural, infectious, vascular, or neoplastic cause (confirmed or suspected by history/imaging).
* Prior botulinum toxin injection or radiofrequency procedure for headache within the last 6 months.
* Known hypersensitivity or allergy to botulinum toxin or to local anesthetics.
* Pregnancy or lactation.
* Neuromuscular junction disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome).
* Medication overuse headache not resolved prior to enrolment.
Study locations
No study locations are listed in the registry data.
Study details
- Start date
- October 1, 2026
- Primary completion date
- October 1, 2027
- Completion date
- December 1, 2027
- First posted
- September 23, 2026
Source and update information
- Source
- ClinicalTrials.gov
- NCT ID
- NCT07837570
- Registry last updated
- September 23, 2026
- QualifiedStudies registry data refreshed
- October 5, 2026
- QualifiedStudies record fetched
- October 5, 2026
View NCT07837570 on ClinicalTrials.gov
Trial information can change. Confirm current study details with the study team or the registry.
About joining clinical research
Find clinical trials you may match with
QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.
Find clinical trials you may match with | Migraines studies | Clinical trial FAQ